Board of directors
Søren Elmann Ingerslev
Mr. Elmann Ingerslev is an attorney at law and partner in the Danish law firm Elmann Advokatpartnerselskab. Mr. Ingerslev has extensive experience in company strategy and acquisitions. He was previously with the Danish law firms Bech-Bruun and Abel & Skovgård Larsen with responsibility for mergers/acquisitions, company law and international business agreements. Mr. Ingerslev currently serves as a non-executive member og the board of directors of several companies.
Ms. Sebree is an experienced pharmaceutical and biotechnology entrepreneur who has successfully founded, financed, grown, and taken public three biopharmaceutical companies. She is currently President of Zynerba Pharmaceuticals (Nasdaq: ZYNE) based in Devon, PA, USA. She co-founded NuPathe Inc. (Nasdaq: PATH) and served as President from February 2005 to March 2014. Prior to NuPathe, Ms. Sebree served as Senior Vice President, Development of Auxilium Pharmaceuticals (Nasdaq: AUXL) from January 2000 to January 2005. Prior to joining Auxilium, Ms. Sebree served as Executive Vice President, United States Operations at IBAH, Inc., a contract research organization. Previously, Ms. Sebree served in a variety of management roles with Abbott Laboratories for over nine years including its development head for psychopharmacology products. Ms. Sebree holds a BS from Texas A&M University.
Kathrin Kortschak is Director at Hestia Investments Ltd., an early-stage biotechnology investment company, as well as co-founder of EB Europe Ltd. a Lifestyle Drinks Manufacturing Startup. Prior to joining Hestia in 2012 Kathrin worked as a Technology Consultant at FimpactT AG in Switzerland. Kathrin has a BA in History & French Literature from The University of Oxford.
Arnstein Endresen has had a long career in Norwegian and international finance and investment activities. He has 10 years of banking experience, he has served as CFO of two companies and he has headed a family office investing in health-related companies and other sectors.
Mr. Endresen is a board member in several private companies, and he is the chairman of Bjørns Invest AS, which is a significant shareholder in Serodus.